Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Inclusion Criteria: 1. Written informed consent must be obtained before any study assessment is performed 2. Diagnosis of visual impairment exclusively due to ME secondary to BRVO 3. BCVA score at Screening and Baseline between 10/40 (0.5) to 20/400 (0.05) on the Snellen chart. 4. Central foveal thickness (CFT) ≥ 300 µm 5. Naive Eyes Exclusion Criteria: 1. Pregnant or nursing (lactating) women 2. Stroke or myocardial infarction less than 3 months before Screening 3. Uncontrolled blood pressure defined as systolic value of \>160 mm Hg or diastolic value of \>100 mm Hg at Screening or Baseline. 4. Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye 5. Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye 6. Neovascularization of the iris or neovascular glaucoma in the study eye 7. Use of any systemic or ocular antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline 8. Panretinal laser photocoagulation performed, anticipated or scheduled in the study eye 9. Focal or grid laser photocoagulation in the study eye 10. Use of intra- or periocular corticosteroids (including sub-Tenon) or ocular anti-VEGF treatment within 3 months before Screening in the study eye 11. Any use of intraocular corticosteroid implants (eg, dexamethasone \[Ozurdex®\], fluocinolone acetonide \[Iluvien®\]) in the study eye